Angela Lamarca, Consultant Medical Oncologist at Jiménez Díaz Foundation University Hospital and The Christie NHS Foundation Trust, shared a post on X by Erman Akkus, Medical Oncology Fellow at Ankara University, about a paper they authored, published in European Journal of Cancer:

“5FU-based Adjuvant chemotherapy for Biliary Malignancies.

Wondering, ‘Did we not know this? What is new?’

We looked at ‘short-term’ (2-y) HR (+’full-time’ HR)

Current SOC mostly beneficial at 2-y, later benefit ‘dilutes’

2-y HR: to be looked at in future trials.”

Quoting Erman Akkus’s post:

“Our study on adjuvant chemotherapy in biliary tract cancers has been published!

I am very thankful to Angela Lamarca for her great mentoring and support along the way.

5FU-based ChT:

RFS and OS benefit in both short and long terms

Benefit is apparent in short-term

No significant benefit with gemcitabine-based ChT.”